Navigation Links
Best Practices Document on Cryoablation Posted on Website of American Urological Association
Date:9/23/2008

IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that the American Urological Association (AUA) has for the first time posted on its website the organization's official "best practice" document on cryoablation for prostate cancer, covering primary, salvage and focal cryoablation, also called cryosurgery. The AUA posting of these clinical guidelines is an acknowledgement of the important advances made in the technology of cryoablation, a minimally invasive treatment for prostate cancer that freezes cancerous tumors to destroy them, said Endocare Chairman, President and CEO Craig T. Davenport.

"This is a principled and unbiased assessment of the effectiveness of cryoablation for treating prostate cancer made by the country's most prestigious association of urologists," Davenport said. "The AUA panel that did the assessment looked at all the published studies of cryoablation and came to the conclusion that it is a valuable treatment that should be considered by prostate cancer patients. The publication of these guidelines helps to place cryoablation more squarely in the mainstream of prostate cancer treatments."

The 51-page document, titled "Best Practice Policy Statement on Cryosurgery for the Treatment of Localized Prostate Cancer" and officially adopted at the recent AUA national conference, specifically notes the "seven-to-eight-year biochemical disease free results of cryosurgery. The literature reports that the morbidity profile associated with cryosurgery has improved in all aspects, including continence, rectal/urethral fistula formation, urethral sloughing, and potency in association with the technological advances over the last 10 to 15 years."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

matt@allencaron.com len@allencaron.com

http://www.allencaron.com http://www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
2. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
3. New Study Recognizes Halogen Customer for Best Practices in Employee Performance and Talent Management
4. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
5. Genstruct and Sirtris Pharmaceuticals Win Bio-IT Worlds Best Practices Award
6. Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry
7. Web-Conferences by Best Practices, LLC for July 2008
8. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
9. First documented case of pest resistance to biotech cotton
10. Researchers Document Rapid, Dramatic Reverse Evolution in the Threespine Stickleback Fish
11. Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... analysis platform specifically designed for life science researchers to analyze and interpret ... Rosalind Franklin, who made a major contribution to the discovery of the ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
Breaking Biology News(10 mins):